A Phase 2a Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of CAD-1883 Oral Treatment in Adults With Essential Tremor
Phase of Trial: Phase II
Latest Information Update: 24 Oct 2019
Price : $35 *
At a glance
- Drugs CAD-1883 (Primary)
- Indications Essential tremor
- Focus Adverse reactions
- Sponsors Cadent Therapeutics
- 22 Oct 2019 Status changed from recruiting to completed.
- 17 Oct 2019 Results presented in the Cadent Therapeutics media release.
- 09 Sep 2019 Planned number of patients changed from 20 to 30.